LIXISENATIDE, BASAL INSULIN AND PREMIXED INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY ORAL ANTIDIABETIC DRUGS: NETWORK META-ANALYSIS AND COST-EFFECTIVENESS ANALYSIS

被引：0
|
作者：
Men, P. [1 ]
Qu, S. [2 ]
Li, C. [3 ]
Zhai, S. [1 ,4 ]
机构：
[1] Peking Univ, Hosp 3, Dept Pharm, Beijing, Peoples R China
[2] IQVIA, Shanghai, Peoples R China
[3] Sanofi, Shanghai, Peoples R China
[4] Peking Univ, Hlth Sci Ctr, Inst Drug Evaluat, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB59
引用
收藏
页码：S150 / S150
页数：1
相关论文
共 50 条
  • [1] Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis
    Men, Peng
    Qu, Shuli
    Luo, Wenting
    Li, Chaoyun
    Zhai, Suodi
    DIABETES OBESITY & METABOLISM, 2020, 22 (01): : 107 - 115
  • [2] COST-EFFECTIVENESS OF LIXISENATIDE COMBINED WITH BASAL INSULIN VERSUS INSULIN REGIMENS FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN IN CHINA
    Men, P.
    Qu, S.
    Luo, W.
    Li, C.
    Zhai, S.
    VALUE IN HEALTH, 2019, 22 : S150 - S150
  • [3] Cost-effectiveness of lixisenatide combined with basal insulin versus insulin regimens for the treatment of patients in China with type 2 diabetes mellitus inadequately controlled by basal insulin
    Men, Peng
    Qu, Shuli
    Luo, Wenting
    Li, Chaoyun
    Zhai, Suodi
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2018, 34
  • [4] Meta-analysis of randomized controlled trials of lixisenatide as add-on to basal insulin and/or oral antidiabetic drugs in patients with type 2 diabetes mellitus
    Wascher, Thomas
    Puig-Domingo, Manuel
    Fonseca, Vivian
    Sangard, Luc
    Lin, Jay
    Davies, Melanie
    Tinahones, Francisco Jose
    Charbonnel, Bernard
    WIENER KLINISCHE WOCHENSCHRIFT, 2013, 125 : S24 - S24
  • [5] Meta-analysis of randomised controlled trials of lixisenatide as add-on to basal insulin and/or oral antidiabetic drugs in patients with type 2 diabetes mellitus
    Puig Domingo, M. L.
    Fonseca, V.
    Wang, E.
    Lin, J.
    Davies, M.
    Tinahones, F. J.
    Charbonnel, B.
    DIABETOLOGIA, 2013, 56 : S362 - S362
  • [6] Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost–Utility Analysis
    Peng Men
    Shuli Qu
    Zhenqiang Song
    Yanjun Liu
    Chaoyun Li
    Suodi Zhai
    Diabetes Therapy, 2020, 11 : 1745 - 1755
  • [7] COMPARATIVE EFFICACY AND SAFETY OF LIXISENATIDE AND INSULIN REGIMENS IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Men, P.
    Qu, S.
    Luo, W.
    Liu, Y.
    Li, C.
    Zhai, S.
    VALUE IN HEALTH, 2018, 21 : S35 - S35
  • [8] Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis
    Men, Peng
    Qu, Shuli
    Song, Zhenqiang
    Liu, Yanjun
    Li, Chaoyun
    Zhai, Suodi
    DIABETES THERAPY, 2020, 11 (08) : 1745 - 1755
  • [9] Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
    Charbonnel, Bernard
    Bertolini, Monica
    Tinahones, Francisco J.
    Puig Domingo, Manuel
    Davies, Melanie
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (06) : 880 - 886
  • [10] SAFETY AND EFFICACY OF INSULIN GLARGINE/LIXISENATIDE AND INSULIN DEGLUDEC/INSULIN ASPART IN TYPE 2 DIABETES PATIENTS NOT CONTROLLED ON BASAL INSULIN: A NETWORK META-ANALYSIS
    Jammah, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A185 - A186
12345